Provided by Tiger Trade Technology Pte. Ltd.

Veracyte

40.87
-1.1600-2.76%
Post-market: 40.870.00000.00%19:30 EDT
Volume:1.00M
Turnover:41.20M
Market Cap:3.29B
PE:29.31
High:42.66
Open:42.61
Low:40.79
Close:42.03
52wk High:60.91
52wk Low:29.46
Shares:80.39M
Float Shares:78.97M
Volume Ratio:1.02
T/O Rate:1.27%
Dividend:- -
Dividend Rate:- -
EPS(TTM):1.39
EPS(LYR):0.8200
ROE:8.77%
ROA:4.09%
PB:2.37
PE(LYR):49.84

Loading ...

Veracyte says OPTIMA trial shows Prosigna test helps 68% of high-risk breast cancer patients avoid chemotherapy

Reuters
·
May 30

Veracyte - Optima Trial Shows Prosigna Test Identifies High-Risk Breast Cancer Patients Who Can Avoid Chemotherapy

THOMSON REUTERS
·
May 30

Veracyte Price Target Maintained With a $48.00/Share by Needham

Dow Jones
·
May 28

Veracyte VP, Chief Accounting Officer Jonathan Wygant sells 24,000 shares for $1.09 million

Reuters
·
May 28

Health Rounds: Veracyte genomic test identifies breast cancer patients who can skip chemo

Reuters
·
May 27

Analysts Are Bullish on These Healthcare Stocks: Veracyte (VCYT), Decibel Cannabis Company (DBCCF)

TIPRANKS
·
May 24

Veracyte director Robert S. Epstein sells 10,000 shares for $440,129

Reuters
·
May 23

Veracyte says OPTIMA trial backs Prosigna-guided chemotherapy decisions in breast cancer

Reuters
·
May 22

Optima Trial Results to Be Presented at Asco Provide New Evidence Supporting Prosigna-Guided Chemotherapy Decisions in Breast Cancer

THOMSON REUTERS
·
May 22

Why Veracyte (VCYT) Is Up 5.4% After Medicare Backs Its TrueMRD Bladder Cancer Test

Simply Wall St.
·
May 21

Analysts Offer Insights on Healthcare Companies: Veracyte (VCYT), Tonix Pharma (TNXP) and Regeneron (REGN)

TIPRANKS
·
May 18

Veracyte TrueMRD test wins Medicare coverage for muscle-invasive bladder cancer monitoring

Reuters
·
May 15

Veracyte Secures Medicare Coverage for Truemrd Monitoring Test in Muscle-Invasive Bladder Cancer

THOMSON REUTERS
·
May 15

Veracyte Inc - Truemrd Monitoring Test Available for Order June 1, 2026

THOMSON REUTERS
·
May 15

Veracyte SVP, General Counsel Annie McGuire disposes 10,204 shares for $398,130.10

Reuters
·
May 09

Veracyte price target raised to $42 from $40 at Canaccord

TIPRANKS
·
May 07

Veracyte price target raised to $52 from $48 at UBS

TIPRANKS
·
May 07

Veracyte (VCYT) Margin Expansion And 166% Earnings Growth Test Premium Valuation Narratives

Simply Wall St.
·
May 07

Veracyte Is Maintained at Buy by UBS

Dow Jones
·
May 07

Stock Track | Veracyte Soars 17.77% Intraday on Strong Q1 Earnings Beat, Raised Guidance and Analyst Upgrades

Stock Track
·
May 06